{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=89",
    "query": {
      "intervention": "Injectable Placebo",
      "page": 89
    },
    "page_size": 10
  },
  "pagination": {
    "page": 89,
    "page_size": 10,
    "total_count": 4225,
    "total_pages": 423,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=90&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=88&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-06T17:46:41.235Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00912496",
      "title": "Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "MF-59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "A/Anhui/05",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 637,
      "start_date": "2010-06",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2013-05-14",
      "last_synced_at": "2026-11-06T17:46:41.235Z",
      "location_count": 10,
      "location_summary": "Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00912496"
    },
    {
      "nct_id": "NCT00261196",
      "title": "Collagenase in the Treatment of Adhesive Capsulitis (Frozen Shoulder)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adhesive Capsulitis",
        "Frozen Shoulder"
      ],
      "interventions": [
        {
          "name": "Collagenase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stony Brook University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2006-01",
      "completion_date": "2009-01",
      "has_results": false,
      "last_update_posted_date": "2019-10-03",
      "last_synced_at": "2026-11-06T17:46:41.235Z",
      "location_count": 1,
      "location_summary": "Stony Brook, New York",
      "locations": [
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00261196"
    },
    {
      "nct_id": "NCT02237196",
      "title": "Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cat Allergy",
        "Cat Hypersensitivity"
      ],
      "interventions": [
        {
          "name": "AMG 157",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cat Immunotherapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cat Immunotherapy Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AMG 157 Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 121,
      "start_date": "2015-03-03",
      "completion_date": "2019-03-04",
      "has_results": true,
      "last_update_posted_date": "2020-05-06",
      "last_synced_at": "2026-11-06T17:46:41.235Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Denver, Colorado • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02237196"
    },
    {
      "nct_id": "NCT06826196",
      "title": "A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alopecia Areata (AA)"
      ],
      "interventions": [
        {
          "name": "ALD-102 Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo or Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Aldena Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 9,
      "start_date": "2025-03-24",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-06T17:46:41.235Z",
      "location_count": 5,
      "location_summary": "Thousand Oaks, California • West Lafayette, Indiana • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Thousand Oaks",
          "state": "California"
        },
        {
          "city": "West Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Burlington",
          "state": "Massachusetts"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06826196"
    },
    {
      "nct_id": "NCT06665646",
      "title": "Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "CD40.HIVRI.Env (VRIPRO)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hiltonol Poly-ICLC-adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 40,
      "start_date": "2025-09-14",
      "completion_date": "2027-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-11-06T17:46:41.235Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06665646"
    },
    {
      "nct_id": "NCT01875003",
      "title": "A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Lebrikizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 346,
      "start_date": "2013-08-13",
      "completion_date": "2016-12-28",
      "has_results": true,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-11-06T17:46:41.235Z",
      "location_count": 16,
      "location_summary": "Mission Viejo, California • Stockton, California • Aurora, Colorado + 12 more",
      "locations": [
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01875003"
    },
    {
      "nct_id": "NCT02073279",
      "title": "Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuromyelitis Optica (NMO)",
        "NMO Spectrum Disorder (NMOSD)"
      ],
      "interventions": [
        {
          "name": "Satralizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 95,
      "start_date": "2014-08-05",
      "completion_date": "2022-01-31",
      "has_results": true,
      "last_update_posted_date": "2023-03-01",
      "last_synced_at": "2026-11-06T17:46:41.235Z",
      "location_count": 20,
      "location_summary": "Aurora, Colorado • Miami, Florida • Vero Beach, Florida + 17 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Vero Beach",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02073279"
    },
    {
      "nct_id": "NCT05105048",
      "title": "A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cytomegalovirus Infection"
      ],
      "interventions": [
        {
          "name": "mRNA-1647",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 9,
      "start_date": "2021-11-08",
      "completion_date": "2023-08-10",
      "has_results": false,
      "last_update_posted_date": "2023-09-11",
      "last_synced_at": "2026-11-06T17:46:41.235Z",
      "location_count": 3,
      "location_summary": "North Hollywood, California • San Diego, California • Honolulu, Hawaii",
      "locations": [
        {
          "city": "North Hollywood",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05105048"
    },
    {
      "nct_id": "NCT00985426",
      "title": "Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "HEPLISAV-B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Engerix-B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Dynavax Technologies Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 521,
      "start_date": "2009-09",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2021-05-19",
      "last_synced_at": "2026-11-06T17:46:41.235Z",
      "location_count": 1,
      "location_summary": "Norfolk, Virginia",
      "locations": [
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00985426"
    },
    {
      "nct_id": "NCT04424693",
      "title": "Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pre-Eclampsia",
        "Diphtheria, Tetanus and Pertussis Vaccine Reaction"
      ],
      "interventions": [
        {
          "name": "Tdap Vaccine Administration",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Institute of Arthritis Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "42 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 42 Years · Female only"
      },
      "enrollment_count": 1600,
      "start_date": "2020-12-01",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-06-16",
      "last_synced_at": "2026-11-06T17:46:41.235Z",
      "location_count": 1,
      "location_summary": "Idaho Falls, Idaho",
      "locations": [
        {
          "city": "Idaho Falls",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04424693"
    }
  ]
}